RESUMO
Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management and outcomes, and characterized omalizumab response with the use of the high-affinity immunoglobulin E (IgE) receptor (FcεRI) and the Urticaria Control Test. An observational, unicentric, ambispective study was conducted from 2007 to 2023. Solar urticaria was diagnosed in 41 patients with a median follow-up of 60 months. Thirteen patients were prescribed omalizumab, with a median treatment time of 48 months. A significant decrease in FcεRI baseline levels and subsequent median increase in Urticaria Control Test was evidenced after omalizumab prescription in all patients. Drug survival at 48 months was at 88.9%. Omalizumab stepping-down protocol led to sustained omalizumab discontinuation in only 1 patient. Median basal Urticaria Control Test was lower (p < 0.01) in patients who were prescribed omalizumab and in patients without remission. This study contributes to our knowledge of omalizumab outcomes in real-life clinical practice and highlights the pathogenic importance of IgE-mediated pathways in solar urticaria, where FcεRI emerges as a possible biomarker of omalizumab response.
Assuntos
Urticária Solar , Urticária , Humanos , Seguimentos , Omalizumab/efeitos adversos , Urticária/diagnóstico , Urticária/tratamento farmacológico , Imunoglobulina ERESUMO
BACKGROUND: Autoimmunity contributes to the pathogenesis of chronic spontaneous urticaria (CSU). The subtyping of CSU has revealed an autoimmune form of CSU. Despite autoimmune diseases having been associated with CSU, there are few prospective studies that have evaluated the characteristics and biomarkers of patients with CSU and autoimmune disease in a real-life practice setting. OBJECTIVE: To evaluate the presence of specific biomarkers for the presence of autoimmune disease in CSU and to analyze the clinical and therapeutic features of patients with CSU and autoimmune disease. METHODS: The clinical, laboratory, and therapeutic features of patients with CSU at a tertiary-level center were prospectively collected. Data obtained were compared in function of the presence/absence of autoimmune disease and typified according to IgE levels. RESULTS: Patients with CSU who had associated autoimmune disease corresponded to middle-aged women with a common pattern of blood test findings: both low baseline IgE and high-affinity receptor of IgE expression, basopenia, eosinopenia, higher baseline erythrocyte sedimentation rate and D-dimer, increased presence of antinuclear antibodies, IgG against thyroid peroxidase, and positive autologous serum skin test result. Total baseline IgE less than or equal to 43.8 IU/mL was both the optimal cutoff to predict autoimmune disease in the CSU cohort and a significant risk factor for the presence of autoimmune disease in the regression analysis. CONCLUSIONS: In real-life clinical practice, characteristics of patients with CSU and autoimmune disease share common features with type IIb autoimmune CSU. Total baseline IgE less than or equal to 43.8 IU/mL has been detected as a possible biomarker of autoimmune disease in patients with CSU.
Assuntos
Doenças Autoimunes , Urticária Crônica , Urticária , Pessoa de Meia-Idade , Humanos , Feminino , Estudos Prospectivos , Autoanticorpos , Biomarcadores , Imunoglobulina E , Doença Crônica , Urticária/etiologiaRESUMO
BACKGROUND: The high-affinity IgE receptor (FcεRI) expression on effector cells has been poorly characterized in patients with chronic urticaria (CU) to date. OBJECTIVES: To investigate the FcεRI expression on blood basophils in a large cohort of patients with CU and its potential relationship with relevant features of the disease. METHODS: Basophil FcεRI expression was measured by flow cytometry in 287 patients with CU (192 with chronic spontaneous urticaria and 95 with chronic inducible urticaria) at their initial evaluation in our department. A control group of healthy nonatopic individuals was included to provide reference data, and the effect of antihistamine and anti-IgE therapy on the basophil FcεRI expression was also evaluated in a cohort of patients with CU. RESULTS: The median FcεRI expression was found significantly higher in patients with CU compared with healthy controls (P < .0001). A positive correlation was found between serum IgE levels and basophil FcεRI expression (R = 0.422; P < .001). Significantly higher FcεRI levels on basophils were detected in patients with CU who presented with concomitant atopic features (P = .003), negative autologous serum skin test (P = .002), negative autologous plasma skin test (P = .009), or undetected levels of antithyroid antibodies (P = 0.01). Baseline FcεRI expression was not related to the activity and duration of the disease, and was not significantly modified during antihistamine therapy; however, it correlated with the clinical response to omalizumab (P = .003). CONCLUSIONS: Although further multicenter studies are needed to corroborate these findings, the assessment of basophil FcεRI levels might be relevant in daily clinical practice supporting an autoimmune pathogenesis and predicting response to anti-IgE treatment.
Assuntos
Basófilos/metabolismo , Urticária Crônica/metabolismo , Receptores de IgE/metabolismo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antialérgicos/uso terapêutico , Asma/epidemiologia , Asma/imunologia , Asma/metabolismo , Autoanticorpos/imunologia , Basófilos/imunologia , Estudos de Casos e Controles , Criança , Pré-Escolar , Urticária Crônica/epidemiologia , Urticária Crônica/imunologia , Comorbidade , Dermatite Atópica/epidemiologia , Dermatite Atópica/imunologia , Dermatite Atópica/metabolismo , Feminino , Citometria de Fluxo , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Imunoglobulina E/imunologia , Iodeto Peroxidase/imunologia , Masculino , Pessoa de Meia-Idade , Omalizumab/uso terapêutico , Receptores de IgE/imunologia , Rinite Alérgica/epidemiologia , Rinite Alérgica/imunologia , Rinite Alérgica/metabolismo , Índice de Gravidade de Doença , Testes Cutâneos , Adulto JovemRESUMO
Resumen La angina mesentérica es un síndrome causado por la inadecuada perfusión sanguínea por parte de los vasos mesentéricos, que resulta en isquemia y a la larga en gangrena de la pared intestinal. Aunque relativamente poco frecuente, es un padecimiento potencialmente mortal. Reportamos un caso de isquemia mesentérica que inició con plenitud, dolor posprandial temprano, distensión abdominal y pérdida de peso en un paciente previamente diagnosticado y tratado de linfoma de colon y adenocarcinoma prostático.
Abstract Mesenteric angina is a syndrome caused by inadequate perfusion from the mesenteric vessels, resulting in ischemia and eventually gut necrosis. Although relatively rare, it is a potential deadly condition. We report a case of mesenteric ischemia which began with bloating, postprandial pain and weight loss on a patient previously diagnosed and treated from colonic lymphoma and prostatic adenocarcinoma.
Assuntos
Antialérgicos/uso terapêutico , Basófilos/imunologia , Omalizumab/uso terapêutico , Receptores de IgE/imunologia , Urticária/tratamento farmacológico , Adolescente , Adulto , Idoso , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Receptores de IgE/biossíntese , Fatores de Tempo , Urticária/imunologia , Adulto JovemRESUMO
Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study investigated the effect of omalizumab on expression of the high-affinity IgE receptor (FcεRI) on blood basophils from patients with active CSU, and its association with the clinical response. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcεRI after 4 weeks, which was maintained throughout the total duration of the treatment. Such evolution was not observed in non-responder patients. Furthermore, non-responders showed significantly lower baseline levels of FcεRI than responders. Baseline basophil FcεRI expression was found to be a potential immunological predictor of response to omalizumab (100% sensitivity and 73.2% specificity). The results of this study contribute to our knowledge of the therapeutic benefit and mechanism of action of anti-IgE therapy in CSU.